Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Response Rates Rule In CGRP Inhibitor Migraine Studies

Executive Summary

The primary endpoint in CGRP inhibitor trials is the average reduction in monthly headache days, but the scientific program committee chair for the recent American Headache Society meeting told Scrip that response rates are more important for doctors who treat migraine patients.


Related Content

Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches
Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most
As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018
Novartis Pharma CEO Paul Hudson Discusses Leadership And Launches
Keeping Track: So. Much. News.
Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions
Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?
Teva Clinches Third Place In CGRP Race With A Phase III Migraine Win
Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts